-
公开(公告)号:US20230257434A1
公开(公告)日:2023-08-17
申请号:US17758825
申请日:2021-01-13
发明人: Shin Gyu Bae , Seung Wook Oh , Joong Hoon Park , Tae Sub Park
IPC分类号: C07K14/47 , C12N5/07 , C07K14/705 , A61K38/17 , A61P21/00
CPC分类号: C07K14/4722 , C12N5/06 , C07K14/70596 , A61K38/17 , A61P21/00 , C12N2510/00
摘要: The present invention relates to cell-derived vesicles comprising target protein Prokineticin receptor 1 (PROKR1), and a therapeutic agent for muscle diseases comprising the same. When applied to myoblasts, the cell-derived vesicles comprising PROKR1 according to the present invention promote muscle differentiation and induce differentiation into myotubes, and can thus be used to prevent or treat muscle diseases and can be widely used in the pharmaceutical industry and the field of health functional foods.
-
公开(公告)号:US20240003792A1
公开(公告)日:2024-01-04
申请号:US17928177
申请日:2021-04-19
申请人: MDimune Inc.
发明人: Shin Gyu Bae , Seung Wook Oh , Dong Woo Han
IPC分类号: G01N1/40
CPC分类号: G01N1/4077 , G01N2001/4088
摘要: Provided is a method for preparing cell-derived vesicles, and more particularly, a method for preparing cell-derived vesicles using a cell extruder, and a syringe-type cell extruder for effectively preparing cell-derived vesicles. According to the present invention, by using the method for preparing the cell-derived vesicles and the cell extruder, it is possible to prepare cell-derived vesicles in a stable, economical, and mass-producible manner.
-
公开(公告)号:US20230033198A1
公开(公告)日:2023-02-02
申请号:US17791850
申请日:2020-09-22
申请人: MDimune Inc.
发明人: Se Hee Kim , Ji Eun Lee , Shin Gyu Bae , Ji Hye Le , Jin Hee Park
摘要: A cell extruder of the present invention comprises: a pressure vessel in which a sample is dispensed; a regulator for adjusting a set pressure of nitrogen gas injected into the pressure vessel and then maintaining a constant pressure; an input valve for opening and closing the injection of nitrogen gas into the pressure vessel; an exhaust valve for removing the internal pressure of the pressure vessel; a filter holder which is provided with a membrane filter soaked with a reagent, so that the sample in the pressure vessel is fed through by the nitrogen gas and crushed into extracellular vesicles; and a collection container in which the extruded sample is stored. According to the present invention, pressure can be freely adjusted by the regulator. That is, the flow rate of the membrane according to pressure can be controlled, thus allowing the validation of a biopharmaceutical production method using an extracellular vesicle extruder. In addition, during cell extrusion, a sintered disc can be removed and cells can be extruded by using only a membrane. Vesicles can be produced within a fine pressure adjustment range (at a fine low pressure at which the membrane is not torn) in which no sintered disc is required.
-
4.
公开(公告)号:US20220339102A1
公开(公告)日:2022-10-27
申请号:US17640997
申请日:2020-09-04
发明人: Shin Gyu Bae , Seung Wook OH , Se Hee Kim , Sung Hoon Han , Jeong Seok Choi , Jeong Mi Kim
IPC分类号: A61K9/127 , A61K35/28 , A61K35/50 , A61K35/545 , A61K35/42 , A61K35/34 , A61K35/19 , A61K9/00 , A61K9/48 , A61K9/20 , A61P1/02
摘要: The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial resistance. A pharmaceutical composition comprising the cell-derived vesicle according to the present invention has the effects of enhancing the proliferation capacity of salivary gland cells damaged by radiation, promoting amylase activity, increasing transepithelial resistance, enhancing the expression of Aquaporin 5, and increasing the amount of saliva secretion. Therefore, the pharmaceutical composition comprising the cell-derived vesicle of the present invention can be used for preventing and treating salivary gland diseases, and thus can be widely used in the pharmaceutical industry and health functional food field.
-
-
-